CGM

Americares Joins the CMA CGM Foundation's Containers of Hope Program

Retrieved on: 
星期二, 一月 30, 2024
Partnership, Health, CMA CGM, CGM, Hospital, Atmosphere, Container, Poverty, Survivor, Disaster, Medicine, APL, CMA, Intermodal freight transport

STAMFORD, Conn., Jan. 30, 2024 /PRNewswire/ -- Americares has joined CMA CGM Foundation's Containers of Hope program, which will transport humanitarian aid for the health-focused relief and development organization for one year.

Key Points: 
  • STAMFORD, Conn., Jan. 30, 2024 /PRNewswire/ -- Americares has joined CMA CGM Foundation's Containers of Hope program, which will transport humanitarian aid for the health-focused relief and development organization for one year.
  • The Foundation will mobilize the CMA CGM Group's expert staff members to support Americares international supply chain and work alongside Americares logistics staff to coordinate the donated shipments.
  • Americares first shipment through the Containers of Hope program is on the way to Ghana, where Americares partners with a local organization to support 250 hospitals, clinics and health centers.
  • In addition, Americares has aid shipments headed to the Dominican Republic, Lebanon and Liberia thanks to the Containers of Hope program.

EQS-News: E-prescriptions new standard in Germany: CGM with positive interim assessment

Retrieved on: 
星期二, 一月 30, 2024
CGM, Patient, Infection, Pharmacy, TI, Smartphone, Pharmacist, Prescription, SMS, Physician, Pharmaceutical industry

EQS-News: CompuGroup Medical SE & Co. KGaA

Key Points: 
  • EQS-News: CompuGroup Medical SE & Co. KGaA
    E-prescriptions new standard in Germany: CGM with positive interim assessment
    The issuer is solely responsible for the content of this announcement.
  • E-prescriptions new standard in Germany: CGM with positive interim assessment
    Koblenz.
  • Pharmacies using CGM Lauer software have redeemed more than 4 million e-prescriptions in the last four weeks.
  • This is CGM's positive interim balance since e-prescriptions became the new standard in ambulatory healthcare at the beginning of the year.

A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2

Retrieved on: 
星期一, 一月 15, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Diabetes, Clinical Trials, Health Technology, Software, Biotechnology, Health, Data Management, CGM, FIN Atlantic Film Festival, Dexcom, EASD, Associate professor, Partnership, Hypoglycemia, University, Risk, DXCM, Diabetic retinopathy, Insulin, G7, Tandem Diabetes Care, AID, Tandem, University of Nottingham, Medical device

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa.
  • The announcement comes just a month after the system launched in the United States and combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2.
  • Additionally, the COMISAIR seven-year follow up demonstrated further substantial reduction in HbA1c when Dexcom CGM is connected to the t:slim X2 insulin pump with Control-IQ technology5.
  • To learn more and to get started with Dexcom G7 and the Tandem t:slim X2 insulin pump, visit Dexcom.co.uk/tandem.

Veri Releases New Metabolic Health Program

Retrieved on: 
星期四, 一月 11, 2024
Biomarker, Science, CGM, Glucose, Habit, Health, Harvard University, Medical device

HELSINKI, Jan. 11, 2024 /PRNewswire/ -- Today, Veri announced the release of its new in-app metabolic health program , the most significant update yet.

Key Points: 
  • HELSINKI, Jan. 11, 2024 /PRNewswire/ -- Today, Veri announced the release of its new in-app metabolic health program , the most significant update yet.
  • Built by Veri's health team in coordination with advisors from Stanford, Duke, and Harvard, the new four-stage program gives members a personalized metabolic health coach in their pocket:
    Daily guidance to help members understand their metabolic health, glucose levels, and how to make improvements.
  • "At Veri, we believe that every person holds the power to achieve optimal metabolic health through sustainable lifestyle change," said Dr. Vimal Ramjee, Director of Heath at Veri.
  • "With that in mind, we created The Veri Program, a personalized four-stage experience that puts your glucose data into context with your lifestyle to deliver impactful, evidence-based action steps that improve metabolic health."

Veri Releases New Metabolic Health Program

Retrieved on: 
星期四, 一月 11, 2024
Biomarker, Science, CGM, Glucose, Habit, Health, Harvard University, Medical device

HELSINKI, Jan. 11, 2024 /PRNewswire/ -- Today, Veri announced the release of its new in-app metabolic health program , the most significant update yet.

Key Points: 
  • HELSINKI, Jan. 11, 2024 /PRNewswire/ -- Today, Veri announced the release of its new in-app metabolic health program , the most significant update yet.
  • Built by Veri's health team in coordination with advisors from Stanford, Duke, and Harvard, the new four-stage program gives members a personalized metabolic health coach in their pocket:
    Daily guidance to help members understand their metabolic health, glucose levels, and how to make improvements.
  • "At Veri, we believe that every person holds the power to achieve optimal metabolic health through sustainable lifestyle change," said Dr. Vimal Ramjee, Director of Heath at Veri.
  • "With that in mind, we created The Veri Program, a personalized four-stage experience that puts your glucose data into context with your lifestyle to deliver impactful, evidence-based action steps that improve metabolic health."

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

Retrieved on: 
星期一, 一月 8, 2024
Software, Mobile, Wireless, General Health, Hardware, Consumer Electronics, Medical Devices, Technology, Health Technology, Wearables, Mobile Technology, FDA, Health, Diabetes, Stelo, Eastern Time Zone, CGM, International, Diet, Insulin, DXCM, Dexcom, Sleep, Growth, Acceleration, Exercise, Pharmaceutical industry

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022.
  • U.S. revenue is expected to be approximately $765 million, representing growth of 26% over the fourth quarter of 2022. International revenue is expected to be approximately $265 million, an increase of 27% over the fourth quarter of 2022.
  • For fiscal 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion, an increase of 24% over 2022.
  • “Through our expanding product portfolio, Dexcom is defining the future of sensing technology and empowering people to take control of health.”
    Dexcom will report its audited full fourth quarter and fiscal 2023 financial results on Thursday, February 8, 2024 after the close of market.

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Retrieved on: 
星期一, 一月 8, 2024
Wearables, Mobile Technology, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Biotechnology, Health, Continuous glucose monitor, Personal, Multimedia, CGM, Caregiver, DME, AID, Disease, Hyperglycemia, Internet, Tandem Diabetes Care, Control, FreeStyle, Medical device

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.
  • View the full release here: https://www.businesswire.com/news/home/20240108667517/en/
    t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration now available in the United States.
  • (Photo: Business Wire)
    Tandem’s t:slim X2 insulin pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute2,3 to the pump.
  • FreeStyle Libre 2 Plus sensor connects via Bluetooth to the Tandem t:slim X2 insulin pump.

Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor

Retrieved on: 
星期一, 一月 8, 2024
Medtronic, Meal, CGM, IOS, FDA, Insulin, Diabetes, CE marking, Hyperglycemia, CE, Outline of health sciences, Android, Snack, EVP, Medical device

DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.*  

Key Points: 
  • Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.
  • *
    The MiniMed 780G system with Simplera Sync™ sensor will be available in Europe via limited release in spring 2024.
  • Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor.
  • With this "treat to target" approach, the system more closely mirrors the glucose levels of someone not living with diabetes.

Nuvilab Innovates Inpatient Nutrition with Food AI at Alexandra Hospital Singapore

Retrieved on: 
星期五, 一月 5, 2024
Patient, Multimedia, CGM, Collection, Digital health, ICT, Diet, Nutrient, Diabetes, Alexandra Hospital, Hospital, Las Vegas Convention Center, LVCC, Child, CES, Bed, Glucose meter

SEOUL, South Korea, Jan. 5, 2024 /PRNewswire/ -- Nuvilab, a leading Food AI company, has announced the expansion of its healthcare services by providing a Nutrition Management Solution for Inpatients at Alexandra Hospital.

Key Points: 
  • SEOUL, South Korea, Jan. 5, 2024 /PRNewswire/ -- Nuvilab, a leading Food AI company, has announced the expansion of its healthcare services by providing a Nutrition Management Solution for Inpatients at Alexandra Hospital.
  • This solution uses an AI Food Scanner to scan each patient's meal tray and analyze individual food intake and nutrients.
  • The system was first tested at Alexandra Hospital in Singapore, where it underwent a seven-week pilot phase to showcase technological advancements in healthcare.
  • Following the successful trial period, Alexandra Hospital recently formalized an agreement with Nuvilab to implement their solution for inpatient care.

Senseonics Holdings, Inc. Announces Business Updates

Retrieved on: 
星期二, 一月 2, 2024
Diabetes, Health Technology, Health, Medical Devices, Gemini, PHC, Marketing, CGM, FDA, Doctor of Philosophy, DTC, Growth, Calibration, Pharmaceutical industry

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates.
  • Significant new lead generation from advertising campaign activities in the fourth quarter by our global commercial partner Ascensia Diabetes Care demonstrated strong patient response to the Eversense message.
  • Now Ascensia is working to accelerate and improve the conversion of those leads by enhancing its CGM-dedicated commercial infrastructure,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.
  • The Company expects to report its full fourth quarter and fiscal year 2023 financial results in the ordinary course later this quarter.